Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SOUTH PLAINFIELD, N.J. and CHARLOTTE, N.C., Nov. 09, 2016 -- Molecular diagnostics company, Admera Health announced the official launch of OncoGxSelect™ while exhibiting at the Association for Molecular Pathology (AMP) 2016 Annual Meeting in Charlotte, North Carolina. OncoGxSelect™ is a Next Generation Sequencing (NGS)-based test for tumor profiling of common cancer types, assaying 12 genes for mutations that align with well-established national guidelines for molecular testing and therapeutic decision making. The panel genes are: ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET and ROS1. Mutations in these genes are frequently the underlying driver of non-small cell lung cancer (NSCLC), melanoma, thyroid, gastrointestinal and breast cancers. Results from OncoGxSelect™ provide targeted therapy recommendations based on gene mutation and tumor type. In addition, relevant, recruiting clinical trials are reported.
OncoGxSelect™ expands Admera’s Oncology Test Portfolio, which also includes OncoGxOne™, a comprehensive 64-gene tumor profiling panel, and PGxOne™ Plus, a pharmacogenomics panel that provides recommendations for over 220 commercial drugs, including cancer, anti-emetic and pain management drugs.
Guanghui Hu, PhD, President and CEO of Admera Health, commented, “The OncoGxSelect™ panel detects clinically actionable mutations that are associated with targeted therapies.” Hu went on to elaborate, “Although Admera already offered comprehensive tumor profiling, with this product launch we can now provide oncologists with a focused panel that follows well-accepted national clinical guidelines.”
Admera Health is exhibiting in Booth #2312 at the AMP 2016 Annual Meeting this week on November 10, 11 and 12.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
